A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma
详细信息 查看全文
- 作者：Sumanta K. Pal ; Harry A. Drabkin ; James A. Reeves ; John D. Hainsworth ; Susan E. Hazel ; Dario A. Paggiarino ; Jon Wojciak ; Gary Woodnutt and Rupal S. Bhatt
- 刊名：Cancer
- 出版年：2017
- 出版时间：February 15, 2017
- 年：2017
- 卷：123
- 期：4
- 页码：576-582
- 全文大小：300K
- ISSN：1097-0142
文摘
Upregulation of sphingosine-1-phosphate (S1P) may mediate resistance to vascular endothelial growth factor (VEGF)-directed therapies and inhibit antitumor immunity. Antagonism of S1P in preclinical models appears to overcome this resistance. In this phase 2 study, the authors assessed the activity of sonepcizumab, a first-in-class inhibitor of S1P, in patients with metastatic renal cell carcinoma (mRCC) with a history of prior VEGF-directed therapy.